Nonalcoholic Steatohepatitis: Current Thinking from the Division of Hepatology and Nutrition at the Food and Drug Administration.

HepatologyVolume 73, Issue 5 p. 2023-2027 Special Article Nonalcoholic Steatohepatitis: Current Thinking From the Division of Hepatology and Nutrition at the Food and Drug Administration Frank A. Anania, Corresponding Author Frank.Anania@fda.hhs.gov Center for Drug Evaluation and Research Office of New Drugs, Office of Inflammation and Immunity, Division of Hepatology and Nutrition, US Food and Drug Administration, Silver Spring, MD ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO: Frank A. Anania, M.D. Center for Drug Evaluation and Research Office of New Drugs, Office of Inflammation and Immunity, Division of Hepatology and Nutrition, US Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 E-mail: Frank.Anania@fda.hhs.gov Tel.: +1-240-402-4975Search for more papers by this authorLara Dimick-Santos, Center for Drug Evaluation and Research Office of New Drugs, Office of Inflammation and Immunity, Division of Hepatology and Nutrition, US Food and Drug Administration, Silver Spring, MDSearch for more papers by this authorRuby Mehta, Center for Drug Evaluation and Research Office of New Drugs, Office of Inflammation and Immunity, Division of Hepatology and Nutrition, US Food and Drug Administration, Silver Spring, MDSearch for more papers by this authorJoseph Toerner, Center for Drug Evaluation and Research Office of New Drugs, Office of Inflammation and Immunity, Division of Hepatology and Nutrition, US Food and Drug Administration, Silver Spring, MDSearch for more papers by this authorJulie Beitz, Center for Drug Evaluation and Research Office of New Drugs, Office of Inflammation and Immunity, Division of Hepatology and Nutrition, US Food and Drug Administration, Silver Spring, MDSearch for more papers by this author Frank A. Anania, Corresponding Author Frank.Anania@fda.hhs.gov Center for Drug Evaluation and Research Office of New Drugs, Office of Inflammation and Immunity, Division of Hepatology and Nutrition, US Food and Drug Administration, Silver Spring, MD ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO: Frank A. Anania, M.D. Center for Drug Evaluation and Research Office of New Drugs, Office of Inflammation and Immunity, Division of Hepatology and Nutrition, US Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 E-mail: Frank.Anania@fda.hhs.gov Tel.: +1-240-402-4975Search for more papers by this authorLara Dimick-Santos, Center for Drug Evaluation and Research Office of New Drugs, Office of Inflammation and Immunity, Division of Hepatology and Nutrition, US Food and Drug Administration, Silver Spring, MDSearch for more papers by this authorRuby Mehta, Center for Drug Evaluation and Research Office of New Drugs, Office of Inflammation and Immunity, Division of Hepatology and Nutrition, US Food and Drug Administration, Silver Spring, MDSearch for more papers by this authorJoseph Toerner, Center for Drug Evaluation and Research Office of New Drugs, Office of Inflammation and Immunity, Division of Hepatology and Nutrition, US Food and Drug Administration, Silver Spring, MDSearch for more papers by this authorJulie Beitz, Center for Drug Evaluation and Research Office of New Drugs, Office of Inflammation and Immunity, Division of Hepatology and Nutrition, US Food and Drug Administration, Silver Spring, MDSearch for more papers by this author First published: 19 December 2020 https://doi.org/10.1002/hep.31687 The views expressed in this report are those of the authors and do not necessarily represent the opinions of the FDA, the US Department of Health and Human Services, or the US government. Potential conflict of interest: Nothing to report. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinked InRedditWechat Volume73, Issue5May 2021Pages 2023-2027 RelatedInformation